TG Therapeutics Raises 2026 Revenue Outlook on Strong Briumvi Sales

TGTX TG Therapeutics Inc

$63.38 +5.94%

View chart & analysis →

CAT +7.21% CMI +3.64% MAT +1.56% ALG +5.44%

1. 1TG Therapeutics (TGTX) raised its full-year 2026 revenue guidance, driven by strong sales growth of its multiple sclerosis treatment Briumvi.
2. 2Second-quarter global revenue reached $240.3 million, with U.S. Briumvi net sales of $227.7 million, up 64% year over year.
3. 3Full-year global revenue is now expected at approximately $950 million, with U.S. Briumvi net sales guided to between $890 million and $905 million.

Source InvestorsHub +5 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →